These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 28987520)

  • 1. Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world.
    Halfon P; Scholtès C; Izopet J; Larrat S; Trimoulet P; Zoulim F; Alric L; Métivier S; Leroy V; Ouzan D; de Lédinghen V; Mohamed S; Pénaranda G; Khiri H; Thélu MA; Plauzolles A; Chiche L; Bourlière M; Abravanel F
    J Hepatol; 2018 Mar; 68(3):595-597. PubMed ID: 28987520
    [No Abstract]   [Full Text] [Related]  

  • 2. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?
    Di Maio VC; Cento V; Aragri M; Paolucci S; Pollicino T; Coppola N; Bruzzone B; Ghisetti V; Zazzi M; Brunetto M; Bertoli A; Barbaliscia S; Galli S; Gennari W; Baldanti F; Raimondo G; Perno CF; Ceccherini-Silberstein F;
    J Hepatol; 2018 Mar; 68(3):597-600. PubMed ID: 28939133
    [No Abstract]   [Full Text] [Related]  

  • 3. "Empirical" retreatment of patients with chronic hepatitis C who failed a first direct-acting antiviral-based regimen.
    Kramer L; Laurain A; Sultanik P; Trémeaux P; Méritet JF; Rosenberg AR; Pol S
    J Hepatol; 2017 Dec; 67(6):1340-1342. PubMed ID: 28843657
    [No Abstract]   [Full Text] [Related]  

  • 4. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals.
    Ahmed A; Felmlee DJ
    Viruses; 2015 Dec; 7(12):6716-29. PubMed ID: 26694454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing HCV treatment failure and the potential of resistance testing in informing second-line therapy options.
    Loggi E; Vukotic R; Andreone P
    Expert Rev Anti Infect Ther; 2018 Nov; 16(11):833-838. PubMed ID: 30336699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C Virus and Antiviral Drug Resistance.
    Kim S; Han KH; Ahn SH
    Gut Liver; 2016 Nov; 10(6):890-895. PubMed ID: 27784846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Direct-acting antiviral-resistant variant].
    Imamura M; Chayama K
    Nihon Rinsho; 2015 Feb; 73(2):322-6. PubMed ID: 25764690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Direct Acting Antivirals treatment failed to cure a patient with chronic hepatitis C due to shifts of viral genotype.
    Lee SW; Yang SS; Lee TY; Yeh HZ; Lu IT; Chang CS
    J Gastrointestin Liver Dis; 2017 Jun; 26(2):205-206. PubMed ID: 28617895
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.
    Wilson EM; Kattakuzhy S; Sidharthan S; Sims Z; Tang L; McLaughlin M; Price A; Nelson A; Silk R; Gross C; Akoth E; Mo H; Subramanian GM; Pang PS; McHutchison JG; Osinusi A; Masur H; Kohli A; Kottilil S
    Clin Infect Dis; 2016 Feb; 62(3):280-288. PubMed ID: 26521268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.
    Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2017 Feb; 89(2):284-290. PubMed ID: 27357737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
    Kinugasa H; Ikeda F; Takaguchi K; Mori C; Matsubara T; Shiraha H; Takaki A; Iwasaki Y; Toyooka S; Yamamoto K
    Antivir Ther; 2016; 21(1):37-44. PubMed ID: 26115551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus.
    Sato K; Uraoka T
    World J Gastroenterol; 2018 Oct; 24(38):4304-4310. PubMed ID: 30344416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant associated variants.
    Premoli C; Aghemo A
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):76-87. PubMed ID: 26448306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The remaining challenges of HCV treatment in the direct-acting antivirals era.
    Kim BK; Ahn SH
    J Gastroenterol Hepatol; 2019 Nov; 34(11):1891-1892. PubMed ID: 31724229
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life.
    Cento V; Barbaliscia S; Lenci I; Ruggiero T; Magni CF; Paolucci S; Babudieri S; Siciliano M; Pasquazzi C; Ciancio A; Perno CF; Ceccherini-Silberstein F;
    Clin Microbiol Infect; 2017 Oct; 23(10):777.e1-777.e4. PubMed ID: 28412381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are we nearing the end in the fight against hepatitis C?
    Chua JV; Kottilil S
    Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):499-500. PubMed ID: 28335650
    [No Abstract]   [Full Text] [Related]  

  • 18. Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with genotype 1 chronic hepatitis C.
    Thiam A; Conway B
    Drugs Today (Barc); 2018 Apr; 54(4):237-244. PubMed ID: 29869645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives.
    Harrington PR; Komatsu TE; Deming DJ; Donaldson EF; O'Rear JJ; Naeger LK
    Hepatology; 2018 Jun; 67(6):2430-2448. PubMed ID: 29194682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure.
    Colpitts CC; Baumert TF
    Viruses; 2016 Aug; 8(8):. PubMed ID: 27537906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.